

Click for [full Prescribing Information](#) for
dextrose monohydrate injection, solution

Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045



March 30, 2026

**Notification of Emergency Date Extension for
Dextrose Injection 25%, USP**

Dear Valued Customer,

Pfizer has received approval from the U.S. Food and Drug Administration (FDA) of our emergency request to extend the use date for three lots of **Dextrose Injection 25%, USP (For Infant Use) 2.5 g/10 mL (250 mg/mL) ANSYR® Plastic Syringe**, NDC 00409-1775-10, to mitigate a shortage of this critical product.

Lots LH7106, LH7108, and LH7103, listed in the table at the end of this letter, have been extended beyond the May 1, 2026 expiration date to October 1, 2026 for **Dextrose Injection 25%, USP (For Infant Use) 2.5 g/10 mL (250 mg/mL) ANSYR® Plastic Syringe**.

If a replacement product becomes available during the extension period, customers are expected to replace and properly dispose of this affected lot as soon as possible. We anticipate that the FDA's [website](#), which lists extended use dates to assist with drug shortages, will also be updated to reflect this information.

If you have any questions, please call our Customer Service Department at 1-844-646-4398.

Thank you,

Brigette DeSimone
Portfolio Director, Premix, ANSYR®, Thrombin®, Heparin
Global Hospital & Biosimilars, U.S. Commercial

Emergency Extended Use Dating: Dextrose Injection 25%, USP (For Infant Use) 2.5 g/10 mL (250 mg/mL) ANSYR® Plastic Syringe

Unit of Sale NDC	Unit of Use NDC	Product Description	Lot(s)	Labeled Expiration Date	Extended Use Date
00409-1775-10	00409-1775-40	Dextrose Injection 25%, USP (For Infant Use) 2.5 g/10 mL (250 mg/mL) ANSYR® Plastic Syringe	LH7106 LH7108 LH7103	5/01/26	10/01/26

© 2026 Pfizer Inc. All rights reserved. March 2026

